Merck starts recruitment for COVID-19 vaccine trial

By: |
September 12, 2020 9:51 AM

The phase 1/2 trial, which is based in Belgium, aims to recruit 260 healthy participants to test the experimental vaccine V591, which it gained access to as part of its May deal for Austrian vaccine maker Themis Bioscience.

Merck & Co Inc, COVID-19 vaccine study, Belgium, AstraZeneca Plc, Moderna Inc , Merck Ebola vaccine, latest news on coronavirus pandemicMerck is late to join the race to develop a safe and effective vaccine for the fast-spreading respiratory illness as rivals Pfizer Inc, AstraZeneca Plc and Moderna Inc are already in late-stage testing. (Reuters photo)

U.S. drugmaker Merck & Co Inc has begun recruiting participants to its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov. The phase 1/2 trial, which is based in Belgium, aims to recruit 260 healthy participants to test the experimental vaccine V591, which it gained access to as part of its May deal for Austrian vaccine maker Themis Bioscience.

The vaccine is based on a modified measles virus that delivers bits of the new coronavirus into the body to prevent COVID-19. Merck is late to join the race to develop a safe and effective vaccine for the fast-spreading respiratory illness as rivals Pfizer Inc, AstraZeneca Plc and Moderna Inc are already in late-stage testing.

The drugmaker is also collaborating with research non-profit IAVI on a second vaccine candidate that uses the same technology as Merck’s Ebola vaccine, ERVEBO. Earlier this month, Chief Executive Kenneth Frazier had said the second candidate is likely to begin trials later this year.

The Wall Street Journal first reported the news on Friday.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Centre ask states to step up efforts against Serotype-II dengue cases; here how to keep your guard up
2Over 78.58 crore COVID-19 vaccine doses provided to states, UTs so far: Centre
3Coronavirus Live Updates: As IPL tournament resumes today in UAE, organisers look to enforce tough Covid rules